Neumann Capital Management LLC Sells 956 Shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Neumann Capital Management LLC decreased its position in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 26.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,702 shares of the financial services provider’s stock after selling 956 shares during the period. Neumann Capital Management LLC’s holdings in iShares Nasdaq Biotechnology ETF were worth $326,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of IBB. Capital Planning Advisors LLC acquired a new position in iShares Nasdaq Biotechnology ETF during the third quarter valued at approximately $36,000. Benjamin F. Edwards & Company Inc. increased its stake in iShares Nasdaq Biotechnology ETF by 16.9% in the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 8,977 shares of the financial services provider’s stock worth $893,000 after buying an additional 1,301 shares during the period. Squarepoint Ops LLC increased its stake in iShares Nasdaq Biotechnology ETF by 16.1% in the 3rd quarter. Squarepoint Ops LLC now owns 87,883 shares of the financial services provider’s stock worth $8,744,000 after buying an additional 12,196 shares during the period. Putnam FL Investment Management Co. increased its stake in iShares Nasdaq Biotechnology ETF by 126.4% in the 3rd quarter. Putnam FL Investment Management Co. now owns 3,810 shares of the financial services provider’s stock worth $379,000 after buying an additional 2,127 shares during the period. Finally, Sandy Spring Bank grew its holdings in iShares Nasdaq Biotechnology ETF by 2.2% during the 3rd quarter. Sandy Spring Bank now owns 31,147 shares of the financial services provider’s stock worth $3,099,000 after acquiring an additional 678 shares in the last quarter. 83.07% of the stock is owned by hedge funds and other institutional investors.

Separately, ValuEngine cut shares of iShares Nasdaq Biotechnology ETF from a “buy” rating to a “hold” rating in a report on Tuesday, October 22nd.

Shares of NASDAQ:IBB traded down $2.88 during trading on Friday, reaching $117.10. The stock had a trading volume of 287,980 shares, compared to its average volume of 2,661,230. iShares Nasdaq Biotechnology ETF has a one year low of $96.03 and a one year high of $123.74. The firm’s 50-day simple moving average is $120.76 and its 200 day simple moving average is $109.68.

iShares Nasdaq Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

See Also: Is it Safe to Invest in Commodities?

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.